Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PRQRBullishIndustry Newsnews

High materiality8/10

ProQR reports strong AX-0810 NTCP engagement; multiple catalysts ahead

Jun 25, 2026, 6:27 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong biomarker-driven NTCP engagement validates the mechanism; multiple near-term catalysts (AX-0811 CTA, China IIT) could drive upside sentiment, though outcomes depend on subsequent safety/efficacy data and regulatory progression.

AI summary

What happened, with direct paths to the underlying reporting

ProQR reported positive Phase 1 data for AX-0810, showing dose-dependent NTCP engagement with up to 8x increases in serum bile acids at 6 mg/kg and no serious adverse events. The 8-week half-life supports sustained activity and reinforces the NTCP program’s potential. Key upcoming milestones include AX-0811 CTA in mid-2026, a China IIT in biliary atresia in 2027, and potential Phase 2 timing mid-2027.

AX-0810 Phase 1 shows dose-dependent NTCP engagement at 3/6 mg/kg.
Serum bile acids up to 8x at 6 mg/kg; exceeds 2x threshold.
No serious AEs; 8-week half-life supports sustained target engagement.
AX-0811 CTA expected mid-2026; IIT in biliary atresia China in 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.